Please login to the form below

Not currently logged in
Email:
Password:

Servier defends Perindopil overcharging claim

Servier refutes claims made by the UK's Department of Health the company is overcharging for high blood pressure and heart disease drug Perindopil

Servier is contesting legal action by the UK's Department of Health (DH), which claims the French drug manufacturer charged £220m too much for its high blood pressure and heart disease drug perindopril.

A report in the UK paper, the Daily Mail, alleges that Health Secretary Andrew Lansley has accused Servier of forcing doctors to pay for expensive versions of the pills when generic ones were available.

Lansley also alleges that the company paid millions of pounds to rivals not to make generic versions, after its patent ran out in 2001, according to the report.

Lansley is leading the action at the High Court with ten strategic health authorities and 157 primary care trusts to reclaim money the NHS was overcharged between 2001 and 2007.

A spokeswoman for Servier said: "We are contesting the claim and we are confident that the right outcome will be reached."

Meanwhile a spokeswoman for the DH told PMLiVE that the department could not comment on ongoing proceedings.

Earlier this year Lansley took legal action against Reckitt Benckiser, claiming nearly £90m for overcharging for heartburn drugs.

7th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics